12:00 AM
 | 
Oct 12, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Selzentry maraviroc regulatory update

FDA's Antiviral Drugs Advisory Committee voted 10-4 in favor of extending the indication of Pfizer's Selzentry maraviroc to include use...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >